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ABSTRACT
OBJECTIVE
To establish the effect of statins on muscle symptoms 
in people who had previously reported muscle 
symptoms when taking statins.
DESIGN
Series of randomised, placebo controlled n-of-1 trials.
SETTING
Primary care across 50 sites in the United Kingdom, 
December 2016 to April 2018.
PARTICIPANTS
200 participants who had recently stopped or were 
considering stopping treatment with statins because 
of muscle symptoms.
INTERVENTIONS
Participants were randomised to a sequence of six 
double blinded treatment periods (two months each) 
of atorvastatin 20 mg daily or placebo.
MAIN OUTCOME MEASURES
At the end of each treatment period, participants rated 
their muscle symptoms on a visual analogue scale (0-
10). The primary analysis compared symptom scores 
in the statin and placebo periods.
RESULTS
151 participants provided symptoms scores for 
at least one statin period and one placebo period 
and were included in the primary analysis. Overall, 
no difference in muscle symptom scores was 
found between the statin and placebo periods 
(mean difference statin minus placebo −0.11, 
95% confidence interval −0.36 to 0.14; P=0.40)). 
Withdrawals because of intolerable muscle symptoms 
were 18 participants (9%) during a statin period and 
13 (7%) during a placebo period. Two thirds of those 
completing the trial reported restarting long term 
treatment with statins.
CONCLUSIONS
No overall effect of atorvastatin 20 mg on muscle 
symptoms compared with placebo was found in 
participants who had previously reported severe 
muscle symptoms when taking statins. Most people 
completing the trial intended to restart treatment with 
statins. N-of-1 trials can assess drug effects at the 
group level and guide individual treatment.
TRIAL REGISTRATION
ISRCTN30952488, EUDRACT 2016-000141-31, 
NCT02781064.
Introduction
Statins reduce cardiovascular disease events in primary 
and secondary prevention, in men and women, and 
across all age groups.1 2 Systematic reviews and meta-
analyses of randomised trials have confirmed the safety 
of statins.3 Although severe adverse effects are rare, 
statins increase the risk of myopathy (absolute excess 
risk about 1 in 10 000 people treated annually), which 
can progress to severe rhabdomyolysis (about 0.2 in 
10 000 people treated annually).3 Uncertainty persists 
about less severe muscle symptoms, however. Many 
people believe that statins frequently cause muscle 
pain,4-6 a view that has been reinforced by results 
from unblinded observational studies6 7 and media 
reports.8-10 This belief has led to patients discontinuing 
treatment,6 11 12 exposing them to an increased risk of 
cardiovascular disease.13
For a patient in routine clinical care, reliably 
determining whether muscle symptoms are caused 
by statins is not easy for the clinician or patient.14-16 
One way to deal with this uncertainty is to conduct 
blinded n-of-1 trials in individual patients with 
symptoms during treatment with statins. N-of-1 trials 
are a randomised trial in individual patients17 that can 
provide information to help determine the best course 
of action in an individual. When a number of n-of-1 
individuals are combined in an analysis, the result can 
also be used to assess the overall effect of a treatment. 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
A causal link between statins and rare but severe muscle adverse effects is well 
characterised but the causal effect of statins on less severe muscle symptoms, 
such as stiffness, pain, and weakness, is uncertain
Widely publicised results of unblinded observational studies has led to many 
patients stopping treatment, believing their muscle symptoms are caused by 
statins, thus increasing morbidity and mortality from cardiovascular disease 
Blinded, randomised n-of-1 trials can provide evidence of the role of statins in 
muscle symptoms
WHAT THIS STUDY ADDS
In a series of randomised, placebo controlled n-of-1 trials, no overall effect 
of statins on the frequency or severity of muscle symptoms was found in 
participants who had previously reported severe muscle symptoms when taking 
statins 
Most people completing the trial planned to restart long term treatment with 
statins 
The n-of-1 trial could be a powerful clinical tool for clinicians and patients to 
determine how best to investigate muscle symptoms associated with statins
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We describe the results of StatinWISE (Statin 
Web-based Investigation of Side Effects), a series of 
n-of-1 trials comparing treatment periods of statins 
and placebo in people who had previously reported 
muscle symptoms when taking statins. Our aim was to 
establish the effect of statins on all muscle symptoms 




StatinWISE was a series of randomised, double blind, 
placebo controlled n-of-1 trials. The overall length 
of the trial was one year for each participant and 
comprised six two month treatment periods (three 
of placebo, three of active treatment) in a randomly 
allocated order.
Participants
Participants were recruited from general practices in 
England and Wales and were considering stopping 
their statin (recruited opportunistically when they 
complained of symptoms during a consultation) or had 
stopped taking a statin in the last three years because 
of muscle symptoms (eligible patients were identified 
through a search of the medical records and invited by 
letter to a screening visit; more details in appendix 3). 
Participants were taking any type of statin at any dose 
before they were enrolled in the trial. Informed consent 
was given by each participant.
We excluded participants with previously raised 
levels of serum alanine aminotransferase (≥3 times the 
upper limit of normal), with persistent, generalised, 
unexplained muscle pain (whether or not associated 
with the use of statins) and levels of creatine kinase 
five times or more the upper limit of normal, any 
contraindications to atorvastatin 20 mg, or who 
the general practitioner considered unsuitable to 
participate in the trial.
Sample size
We planned to recruit 200 participants to provide 
about 90% power to detect a treatment effect of at least 
one full unit on the visual analogue scale, assuming 
a type I error of 5% and allowing for loss to follow-up 
of 40% of participants (see sample size calculation in 
appendix 1).
Randomisation and masking
Randomisation codes were generated and held securely 
by an information technology team and sponsor 
representative at the London School of Hygiene and 
Tropical Medicine Clinical Trials Unit, who were 
independent of the StatinWISE trial management 
team. The codes were made available to Sharp Clinical 
Services (UK), a good manufacturing practice certified 
clinical trial supply company, for the treatment packs 
to be manufactured according to the randomisation 
list.
Participants were allocated with equal probability 
to one of eight possible sequences (appendix fig 1), 
which ensured that all participants received one 
period of statins and one period of placebo in their first 
two treatment periods (in random order) and no one 
was allocated to three sequential periods of the same 
treatment. Randomisation codes were generated and 
held securely and confidentially by an information 
technology team and sponsor representative at the 
London School of Hygiene and Tropical Medicine 
Clinical Trials Unit who were independent of the 
StatinWISE trial management team and the general 
practitioner surgery staff, ensuring that the allocations 
were concealed. A physical copy of the randomisation 
codes was stored in a sealed and signed envelope in 
the locked office of the director of the clinical trials 
unit. The codes were made available to Sharp Clinical 
Services (UK) (marketing authorisation No 10284). 
Placebo was manufactured and packaged by Sharp 
Clinical Services (UK) Ltd to match atorvastatin. More 
information on drug manufacture is available in the 
protocol (appendix 3).
Interventions and outcomes
Daily atorvastatin (20 mg) was compared with matching 
placebo over six two month treatment periods. The 
primary outcome was self-reported muscle symptoms, 
defined as pain, weakness, tenderness, stiffness, or 
cramp of any intensity. The primary outcome was 
measured each day with a validated visual analogue 
scale (0-10, score 0=no symptoms, 5=moderate 
symptoms, and 10=worst possible symptoms)18 for the 
last seven days of each treatment period (appendix 1 
has more detail on data collection tools). We aimed to 
collect symptoms with a web based database or mobile 
app but our patient representatives recommended that 
participants should also be allowed to submit their 
scores over the telephone or by paper questionnaire. 
Participants reporting by telephone were asked to 
score their symptoms on an analogue severity scale, 
from 0 to 100 (with scores divided by 10 to match the 
visual scale), and did not use a visual scale. Measuring 
symptoms only during the last week of each two month 
treatment period was designed to avoid any carryover 
effect.
A secondary outcome was collected three months 
after the end of the final treatment period: we 
determined whether the participant had, or intended to, 
restart treatment with statins, and asked participants 
whether they had found their own trial result helpful 
in making the decision about their future use of statins. 
Other prespecified secondary outcomes (described in 
the protocol, appendix 3) were collected on the last day 
of each two month treatment period by questionnaire. 
These included binary measures for experience of 
muscle symptoms and if the symptoms were attributed 
to the study drug treatment, site of muscle symptoms, 
visual analogue scale scores (0-10) for the effect of 
their muscle symptoms on general activity, mood, 
ability to walk, normal work, relationships with other 
people, sleep, and enjoyment of life, and any other 
symptoms that the participant attributed to the study 
drug treatment. The questions related to symptoms 
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experienced during the whole treatment period. 
Adherence to the study drug treatment was self-
reported and verified by a drug accountability count of 
returned packs of drugs.
Statistical methods
Individual n-of-1 trials
At the end of each n-of-1 trial (after period 6, or at 
withdrawal), participants received numerical and 
graphical summaries of their individual data, in 
relation to their statin and placebo periods (appendix 
4) and were invited to discuss these with their general 
practitioner, who also received a copy. The n-of-1 trial 
methodology allows for the use of the personalised 
results document. Participants were then asked if 
the personalised results document was helpful and 
whether they would restart treatment with statins.
Combined analysis of n-of-1 trials
To estimate the overall effect of the trial treatment on 
muscle symptom scores, data from each n-of-1 trial 
were aggregated. The primary analysis included all 
participants who entered data on muscle symptoms 
at least once during a treatment period with statins 
and at least once during a treatment period with 
placebo. Statistical information about the treatment 
effect is limited if participants enter data only under 
one condition because the mixed models used in 
our primary analysis rely on within participant 
information. The primary analysis was a linear mixed 
model for visual analogue scale muscle symptom scores 
with random effects for participant and treatment. 
The analysis accounted for correlation between the 
seven daily measurements by modelling the residual 
errors with a first order autoregressive error structure 
within each treatment period, and non-normality of 
the symptom scores by robust standard errors. For 
the primary outcome, 95% confidence intervals are 
presented with a two sided P value. For secondary 
outcomes, 99% confidence intervals are presented to 
account for multiple testing.
Period effects were explored in sensitivity analyses. 
To assess differences between data collection methods, 
the primary analysis was repeated adjusting for the 
data collection method and allowing the treatment 
effect and the residual variance to vary by the data 
collection method.
Secondary analyses
The binary measure of whether the participant reported 
having or not having muscle symptoms during that 
treatment period (with participants contributing one 
response per period until completion or withdrawal) 
was analysed with a logistic mixed model with random 
participant and treatment effects. This binary measure 
was then combined with the follow-up question about 
attribution, to obtain one binary measure of whether 
the participant reported having muscle symptoms that 
could not be attributed to another cause (eg, strenuous 
exercise). This binary measure was analysed with a 
similar logistic mixed model.
Secondary outcomes of the effect of the statin 
on other aspects of life were analysed similarly to 
the primary outcome, omitting the autoregressive 
correlation structure. We recorded the number and 
proportion of participants who decided to continue to 
use statins three months after their treatment ended 
(month 15). Symptom scores during treatment with 
statins and placebo were summarised according to a 
participant’s decision about whether to continue to 
use statins at month 15.
We used graphical and descriptive summaries to 
explore how withdrawals and adherence related to the 
statin and placebo periods. In patients who had not 
withdrawn before the start of the trial, a multinomial 
model was used to compare the probabilities of 
participants withdrawing during a placebo period, 
withdrawing during a statin period, or completing 
the trial. Analyses were repeated restricting to 
withdrawals because of intolerable symptoms. Risk 
ratios, P values, and 95% confidence intervals were 
calculated. All analyses were prespecified. A data 
monitoring committee oversaw the study. The trial was 
registered on ISRCTN registry (ISRCTN30952488), the 
European Union Drug Regulating Authorities Clinical 
Trials Database (EUDRACT 2016-000141-31), and on 
Clinicaltrials.gov (NCT02781064).
Patient and public involvement
A StatinWISE patient involvement group was involved 
in trial design, specifically the packing and distribution 
of the drug, design of the data collection tools, and the 
content and wording of patient documents. The group 
was involved in trial conduct through membership in 
the Trial Steering Committee and provided substantial 
input into the individual participants’ results feedback 
document. Patient representatives provided active input 
into the interpretation and presentation of the results.
Results
Recruitment, participant flow, and baseline 
characteristics
We recruited 200 participants between 20 December 
2016 and 5 April 2018, and the last participant follow-
up was on 5 July 2019. Mean age was 69.1 (standard 
deviation 9.5), 115/200 (58%) participants were men, 
and 140/200 (70%) had a history of cardiovascular 
disease. Median total cholesterol concentration was 
5.3 mmol/L (interquartile range 4.4 to 6.2) (table 1).
Numbers analysed
Of the 200 participants, 151 (76%) provided one or 
more visual analogue scale measurements in both a 
statin period and a placebo period and were included in 
the primary analysis (fig 1); 86/200 (43%) participants 
did not complete the whole trial (two died, four were lost 
to follow-up, and 80 withdrew). The 151 participants 
included in the primary analysis contributed 2638 
measurements during 392 statin periods and 2576 
symptom score measurements during 383 placebo 
periods. Each of these measurements contributed to 
the primary analysis. The mean number of scores per 
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participant was 34.5 (range 8-42). Appendix figure 
3 shows the distribution of symptom scores across 
all periods. In period 1, 164/200 (82%) participants 
provided at least one daily report of muscle symptoms 
on the visual analogue scale, decreasing to 75% in 
period 2 (n=149/200) and to 58% (n=115/200) in 
period 6. Most (181/200, 91%) participants provided 
outcome data online or by paper (appendix table 1).
Primary outcome
The observed mean muscle symptom score on the 
visual analogue scale was lower during statin treatment 
periods (mean 1.68, standard deviation 2.57) than 
during placebo periods (1.85, 2.74). We found no 
differences in mean muscle symptom scores between 
the statin and placebo periods (mean difference 
statin minus placebo −0.11 (95% confidence interval 
−0.36 to 0.14); P=0.40). Participants contributed 
different numbers of periods to the analysis and so 
the estimated treatment effect was not identical to 
the crude difference in means. We found no evidence 
that the effect of statins on the primary outcome was 
modified by the method of data collection (appendix 
table 2).
Secondary outcomes
We found no evidence of an effect of statins on the 
occurrence of muscle symptoms overall (odds ratio 
1.11; 99% confidence interval 0.62 to 1.99) or for 
muscle symptoms that could not be attributed to 
another cause (1.22; 0.77 to 1.94) among the 152 
participants who contributed at least one secondary 
outcome measurement in a statin period and one in a 
placebo period (one additional participant provided 
secondary outcome data through our questionnaire 
than provided primary outcome data (table 2). For the 
other secondary outcomes (general activity, mood, 
ability to walk, normal work, relationships with other 
people, sleep, and enjoyment of life), we found no 
differences in symptom scores measured on the visual 
analogue scale between the statin and placebo periods 
(table 3). Site of symptoms was reported in 481/493 
(97.6%) reports of muscle symptoms; most (312/481, 
64.9%) were in the lower limbs (appendix table 3).
Participant decisions about ongoing use of statins
Of the 114 participants who completed six treatment 
periods, 113 (57% of 200 randomised participants) 
received their results during an end of trial 
discussion. One participant did not attend. Of these 
113 participants, 99/113 (88%) said that the trial 
had been helpful and 74/113 (66%) said that they 
had already or intended to resume taking statins. Of 
the 113 participants, 17 (15%) had a mean muscle 
symptom score at least one unit higher during the 
statin than the placebo periods and had been informed 
that statins might be contributing to their muscle 
symptoms. Among these 17 patients, nine (53%) said 
they planned to restart treatment with statins. Of the 
remaining 96 participants who had been informed that 
statins were unlikely to be contributing to their muscle 
symptoms, 65 (68%) said they planned to restart 
treatment with statins.
Withdrawals
Table 4 shows the reasons for withdrawal. Of the 80 
withdrawals, 34/80 (43%) occurred during a statin 
period, 39/80 (49%) during a placebo period, and 
7/80 (9%) after randomisation but before the study 
drug was taken. Overall, few participants withdrew 
Table 1 | Baseline characteristics
Characteristic Frequency (%)*
Total No of randomised participants 200 (100)
Age (mean, SD) 69.1 (9.5)
Age
 35-49 7 (3.5)
 50-64 49 (24.5)
 65-79 115 (57.5)
 ≥80 29 (14.5)
Sex
 Women 85 (42.5)
 Men 115 (57.5)
Ethnicity
 Asian 11 (5.5)
 Black 8 (4)
 Other 2 (1)
 White 179 (89.5)
Smoking status
 Current smoker 14 (7)
 Ex-smoker 105 (52.5)
 Non-smoker 81 (40.5)
Diabetes
 No 167 (83.5)
 Yes 33 (16.5)
Cardiovascular disease history
 No 60 (30)
 Yes 140 (70)
Cholesterol (mmol/L; median (IQR))† 5.3 (4.4-6.2)
QRISK2 score, for participants with no history of  
cardiovascular disease (median (IQR)) 18.3 (9.6-28.8)
Statin status at recruitment
 Stopped 151 (75.5)
 Considering stopping 49 (24.5)
IQR=interquartile range; SD=standard deviation.
*Unless otherwise indicated.
†One value missing; values taken within the three years preceding 
recruitment, and therefore some patients will have been taking statins 
and others not.
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Fig 1 | Recruitment and participant flow. *Seven of these 46 participants never received 
treatment (one withdrew consent, one had intolerable symptoms, one had clinical 
concerns, and four for other reasons). †152 participants were included in the secondary 
analysis (one participant completed the patient questionnaire in two periods but the 
primary outcome in only one)
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because of muscle symptoms. During statin periods, 
18/200 (9%) participants withdrew because of 
intolerable symptoms compared with 13/200 (7%) 
during placebo periods. Appendix figure 4 shows 
the mean symptom scores for those who withdrew 
versus those that did not withdraw. Among the 193 
participants who had not withdrawn before the start of 
the trial, our multinomial models showed no evidence 
of a difference in the probability of withdrawals during 
a statin period compared with a placebo period, either 
overall (risk ratio 0.87, 95% confidence interval 0.55 
to 1.38; P=0.56) or because of intolerable muscle 
symptoms (1.38, 0.66 to 2.83; P=0.56).
Adherence
Adherence reported by participants was confirmed 
by verification of the number of pills remaining in 
the returned drug treatment packs. Adherence to the 
study drug treatment was high, with at least 80% of 
participants reporting taking their drug treatment 
“every day” or “most days” during each period, for 
participants who had not yet withdrawn (appendix 
table 4 and appendix fig 2).
Adverse events
During the trials, 13 serious adverse events were 
recorded; none was considered attributable to the 
study drug treatment. Two fatal events (one during 
statin treatment and one after the end of treatment) 
and 11 non-fatal events (five during statin treatment 
and six during placebo) were found.
Discussion
Principal findings
This series of n-of-1 trials recruited participants who 
were considering stopping or had stopped their statin 
treatment because of muscle symptoms. We found 
no differences in the frequency or severity of muscle 
symptoms between the statin and control periods. 
Also, we found no differences for the effect of muscle 
symptoms on aspects of daily life (general activity, 
mood, ability to walk, normal work, relationships with 
other people, sleep, and enjoyment of life) between the 
statin and control periods. Missing outcome data were 
equally distributed between the statin and placebo 
periods, making it unlikely that muscle symptoms 
contributed to missed outcome data collection. Of 
those completing the trial, most (88%) said that their 
n-of-1 trial had been helpful, with nearly two thirds 
reporting that they intended to restart treatment with 
statins.
We found no evidence of a difference in withdrawals 
between the statin and placebo periods but StatinWISE 
was not powered to detect a difference in withdrawals 
between periods, and our estimates did not exclude 
a difference. This highly selected population of 
participants had identified themselves at the start 
of the study as experiencing symptoms when taking 
statins that were severe enough to stop treatment. 
Withdrawal because of intolerable symptoms, 
however, was uncommon, and the excess comparing 
statins and placebo was only 2%.
Comparison with other literature
StatinWISE and the concurrent SAMSON trial19 are 
the first large series of n-of-1 trials to investigate the 
effect of statins on muscle symptoms. Our findings 
support the limited evidence from one small n-of-1 
trial and large systematic reviews and meta-analyses 
of randomised trials that have not established a clear 
effect of statins on muscle symptoms in the absence of 
myopathy.2 3 20 21 Our data agree with the findings of 
the ODYSSEY ALTERNATIVE trial22 and the GAUSS-3 
trial,23 which found that only a small proportion of 
patients intolerant to statins developed intolerable 
muscle symptoms when taking statins compared with 
placebo. Our data also agree with findings from a 
smaller cohort of patients with idiopathic inflammatory 
myopathies whose myalgia was not aggravated by 
statins.24 An ongoing meta-analysis25 is investigating 
data on adverse events from blinded, randomised trials 
of statins. Our findings clearly indicated that most 
patients taking statins did not experience symptoms 
causally related to their statin, highlighting the 
importance of blinding when assessing adverse effects.
Observational studies have reported adverse effects 
on muscle,26 and the experience of muscle symptoms 
when taking statins in clinical practice causes patients 
to stop treatment.6 Various explanations have been 
offered: the nocebo effect, in which expectations 
of adverse effects might lead patients to attribute 
Table 2 | Estimated effects for secondary outcomes comparing statin with placebo periods (from participant 
questionnaire; n=152)
No (%) of participants
Odds ratio (99% CI)
Statin periods Placebo periods
Muscle symptoms 248/397 (62.5) 239/388 (61.6) 1.11 (0.62 to 1.99)
Muscle symptoms, not attributed to other causes 216/397 (54.4) 200/388 (51.6) 1.22 (0.77 to 1.94)
Participants contributed multiple periods to these summaries and so the odds ratio cannot be directly calculated from these fractions. Odds ratios above 
1 indicate higher odds on statins.
Table 3 | Estimated effects for secondary outcomes comparing statin and placebo 
periods (from participant questionnaire) for aspects of daily life (n=152)
Mean difference, cm (99% CI)
General activity 0.09 (−0.25 to 0.42)
Mood 0.26 (−0.04 to 0.56)
Ability to walk 0.11 (−0.22 to 0.43)
Normal work 0.15 (−0.17 to 0.46)
Relationships with other people 0.15 (−0.09 to 0.39)
Sleep −0.02 (−0.32 to 0.29)
Enjoyment of life 0.13 (−0.22 to 0.48)
Each analysis includes all participants with at least one measurement for that outcome during a placebo period 
and at least one measurement during a statin period. One additional participant provided secondary outcome 
data through our questionnaire than provided primary outcome data. Values greater than zero indicate more 
symptoms on statins.
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muscle symptoms during treatment with statins to the 
statins themselves.27 Also, muscle aches and pains 
are common among the age group taking statins and 
might occur coincidentally with the use of statins, 
leading patients and clinicians to erroneously attribute 
pain to statins.28 Lack of randomisation and blinding 
in observational studies imply that for a subjective 
symptom, such as muscle pain, an association with the 
use of statins might not be causal. The large proportion 
of our participants who intended to restart treatment 
with statins after their trial is in line with observational 
data showing that rechallenge with statins can be 
tolerated by most patients.29 30
Strengths and weaknesses of the study
A common criticism of large placebo controlled trials 
of statins is that patients most likely to experience 
side effects are not included. StatinWISE included 
only patients who had experienced symptoms during 
treatment with statins. Also, in some larger trials, 
participants were not asked specifically about muscle 
symptoms and their intensity; in StatinWISE, patients 
were asked directly about the intensity of their muscle 
symptoms. We minimised bias and confounding 
by collecting data on muscle symptoms in a series 
of double blind trials, with randomised statin and 
placebo treatments.
Within subject designs tend to have greater 
statistical power, which was increased by repeated 
measurements in each treatment period, allowing us 
to investigate differences between statins and placebo 
with greater precision. The design also allowed us to 
feed back information to participants about whether 
their muscle symptoms occurred more frequently 
during the statin or placebo period, so that they could 
decide whether to continue treatment with statins.
In conducting this series of trials, we allowed 
participants to determine whether their symptoms 
were likely to be caused by statins. In this real world, 
general practice setting, we have shown the potential 
of these studies to be used in everyday clinical practice. 
The n-of-1 trial could be adopted by clinicians who are 
looking to establish the best course of treatment for 
patients, in general practice or outpatient settings, 
who present with muscle symptoms associated with 
statins.
Of the 200 randomised participants, 86 did not 
complete the whole trial, of whom 49 did not provide 
sufficient data to contribute to the primary analysis. 
Adherence was similar for the statin and placebo 
periods, and the trial was adequately powered to 
account for this level of attrition. We did not measure 
levels of creatine kinase in participants who withdrew 
from the study so we do not know what proportion 
of participants had biochemical evidence of muscle 
effects. For simplicity, we assessed the effect of one 
statin, atorvastatin 20 mg, on muscle symptoms. Our 
results, therefore, might not apply to higher doses of 
atorvastatin or to other statins. Although we intended 
to collect outcomes with web based methodology, 
over half of the participants preferred to report their 
symptoms on paper or by telephone. Our two month 
treatment periods were designed to be long enough to 
allow the previous treatment to washout, and to allow 
the current treatment to have an effect. It is possible, 
however, that this time period was not long enough for 
some of our patients, and that the scores on the visual 
analogue scale were affected by treatment from the 
previous period.
Interpretation and future research
The analysis of our series of n-of-1 trials found no overall 
effect of statins on muscle symptoms in participants 
selected on the basis of having experienced severe 
muscle symptoms but no important increases in levels 
of enzymes during previous treatment with statins. The 
lack of effect in patients completing the trial, combined 
with the low number of withdrawals owing to muscle 
symptoms, suggests a nocebo effect among users of 
statins, or of high tolerance to blinded rechallenge.
Treatment with statins for those at high risk has 
potential health benefits that are lost by those who 
stop treatment. The availability of n-of-1 trial packs 
in clinical care would allow patients and clinician to 
replicate this study in individuals, for any statin and 
at any dose to suit clinical needs, in primary care or 
in lipid clinics. Our results suggest that most patients 
would restart treatment after such a trial. Future work 
could focus on conducting n-of-1 trials for other types 
of statins and higher doses, and for other drugs which 
are associated with transient adverse effects.
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Table 4 | Reasons for withdrawals by treatment
All withdrawals 
(n=80)
During a placebo 
period (n=39)




Withdrawal of consent 16 (8) 8 (4) 7 (3.5) 1 (0.5)
 Muscle symptoms* 1 (0.5) 1 (0.5) 0 0
 Non-muscle symptoms* 4 (2) 2 (1) 2 (1) 0
 Not related to drug treatment* 3 (1.5) 1 (0.5) 2 (1) 0
 Switched to statin* 0 0 0 0
 No reason given* 8 (4) 4 (2) 3 (1.5) 1 (0.5)
Intolerable muscle symptoms 32 (16) 13 (6.5) 18 (9) 1 (0.5)
Clinical concern 14 (7) 9 (4.5) 4 (2) 1 (0.5)
 Muscle symptoms* 1 (0.5) 1 (0.5) 0 0
 Non-muscle symptoms* 4 (2) 2 (1) 2 (1) 0
 Not related to drug treatment* 5 (2.5) 3 (1.5) 2 (1) 0
 Switched to statin* 4 (2) 3 (1.5) 0 (0) 1 (0.5)
Other 17 (8.5) 8 (4) 5 (2.5) 4 (2)
 Non-muscle symptoms* 4 (2) 4 (2) 0 0
 Not related to drug treatment* 13 (6.5) 4 (2) 5 (2.5) 4 (2)
Unknown 1 (0.5) 1 (0.5) 0 0
Data are number (%) of participants from 200 participants randomised to a sequence of treatments.
*Post hoc finer categorisation.
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